ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

DNAnexus Strengthens Leadership Team with Appointment of Dr. Asha S. Collins as General Manager of Biobanks

Industry veteran will lead the UK Biobank platform and other global biomedical data initiatives driving the future of precision medicine

DNAnexus, Inc., the leading cloud-based biomedical and data management platform for healthcare and life sciences, today announced the appointment of Asha S. Collins, PhD, to General Manager, Biobanks. Dr. Collins will be responsible for managing the UK Biobank project and supporting the company’s diverse global health research community. She will report to DNAnexus’ Chief Executive Officer, Richard Daly.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005211/en/

Asha S. Collins, PhD, General Manager of Biobanks at DNAnexus, Inc. (Photo: Business Wire)

Asha S. Collins, PhD, General Manager of Biobanks at DNAnexus, Inc. (Photo: Business Wire)

DNAnexus has built the cloud-based research analysis platform for UK Biobank, the world’s most comprehensive biomedical database. More than 22,000 researchers around the globe are currently using UK Biobank database to access and analyze genetic, lifestyle, and health information from 500,000 UK participants. Over the past four years, the database has enabled numerous scientific discoveries that have accelerated research for common human disorders, such as cancer, heart disease, and dementia. As part of her new role, Dr. Collins will work with the UK Biobank team to further develop the analytics capabilities, optimize the user experience, and support the platform as the database scales to more than 40 petabytes in the next five years.

“Asha brings a breadth of unique international expertise and a proven track record of scaling biopharma businesses,” said Richard Daly. “DNAnexus is privileged to partner with UK Biobank and provide the cloud-based bioinformatics platform that enables the world’s largest collaborative scientific biobank community. Asha will help us build on the recent success of the UK Biobank partnership and facilitate global health research collaborations redefining how researchers and clinicians access, analyze, and translate the world’s biomedical data.”

Dr. Collins has spent the past 20 years as a biologist, strategist, and operational leader focused on transforming and scaling biopharma and healthcare companies. Previously, she was the Head of U.S. Clinical Operations at Genentech, where she was responsible for executing in-sourced, late-stage, pivotal clinical trials for the entire Genentech / Roche product portfolio. Prior to that, Dr. Collins was Vice President and General Manager for the U.S. Clinical Trial Sourcing business at McKesson Corporation and worked as a senior executive focused on life sciences strategy and operations for Fortune 500 companies at Deloitte and Quintiles Consulting. Dr. Collins is also an Aspen Institute Health Innovator Fellow, an independent Corporate Director for IDEXX Laboratories, a member of the Scientific Advisory Board for the Translational Research Institute for Space Health, and a mentor for Backstage Capital. She also worked on The Cancer Genome Atlas project (TCGA), where she focused on managing stakeholder and public communications, as well as the integration of business requirements for the first public database. Dr. Collins earned her PhD in Cancer Biology from the University of Wisconsin-Madison and a Bachelor of Science in Biology from the University of Pittsburgh.

Throughout her career, Dr. Collins has been focused on innovation and improving healthcare access. She helped launch a novel healthcare research effort in East Africa and currently co-leads a community dedicated to supporting underrepresented healthcare entrepreneurs.

“Today, we are only at the tip of the iceberg when it comes to realizing the full potential of biomedical data,” said Dr. Collins. “I’m looking forward to working with the global research community to expand access to data and analysis tools that generate life-changing insights.”

To learn more about DNAnexus-powered UKB Research Analysis Platform, sign up here.

About DNAnexus

DNAnexus is a secure, trusted cloud platform for accessing, analyzing, and translating the world’s biomedical data—powering a collaborative scientific community that generates life-changing research and breakthroughs in precision medicine. The platform delivers unparalleled scalability, flexibility and reproducibility that drive improved diagnostics, new targeted therapies, and better patient care through a collaborative, yet secure and compliant environment. DNAnexus is the trusted partner to Life Sciences, Healthcare, Government, and Academia in over 48 countries, and serves the world’s top pharmaceutical companies and national research initiatives. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.

@DNAnexus strengthens leadership team with appointment of Dr. Asha S. Collins as General Manager of Biobanks. She will be responsible for managing the UK Biobank project and supporting the company’s diverse global health research community

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.97
+23.11 (10.37%)
AAPL  272.04
+0.64 (0.24%)
AMD  255.25
+0.41 (0.16%)
BAC  52.95
-0.08 (-0.14%)
GOOG  280.25
-1.65 (-0.59%)
META  652.02
-14.45 (-2.17%)
MSFT  517.16
-8.60 (-1.64%)
NVDA  202.83
-0.06 (-0.03%)
ORCL  260.00
+3.11 (1.21%)
TSLA  449.63
+9.53 (2.17%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.